August 12, 2019
Axcella Health posts second quarter 2019 net loss of $14.4 million
Initiated a Non-IND, IRB-Approved Clinical Study for AXA1957 in adolescent subjects with NAFLD Announced the publication in Frontiers of data…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Axcella Health
April 2, 2019
Axcella Announces Patent Issuance for AXA™ Candidate AXA1125 Methods of Use
Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio Claims cover methods of use of EMM compositions in liver…